Oragenics, Inc. Announces Notification of Noncompliance with NYSE MKT Continued Listing Standards May 13, 2016
Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol May 2, 2016
